(184 days)
No
The device description and performance studies focus on the mechanical properties and design of the hip implant components, with no mention of AI or ML.
Yes
Reason: The device is a hip implant system, which is used to treat various conditions like arthritis, fractures, and avascular necrosis, directly addressing and alleviating these medical issues in patients.
No
This device is described as a hip system, including acetabular components and femoral stems, used for joint replacement and revision surgeries. Its purpose is therapeutic, not diagnostic.
No
The device description clearly details physical components made of Titanium alloy and UHMWPE, indicating it is a hardware medical device.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use/Indications for Use: The indications clearly describe the device's use in surgical procedures to replace or revise hip joints due to various conditions. This is a therapeutic and reconstructive purpose, not a diagnostic one.
- Device Description: The description details the physical components of a hip implant (acetabular shell and insert). This is a medical device intended for implantation, not for analyzing samples from the human body.
- Lack of IVD Characteristics: There is no mention of the device being used to examine specimens (blood, tissue, etc.) to provide information for diagnosis, monitoring, or screening.
The device is a surgical implant used in orthopedic procedures.
N/A
Intended Use / Indications for Use
Indications for use with the CONSENS® Hip System or UNISYN™ Hip System:
- A) Significantly impaired joints resulting from rheumatoid, osteo, and post-traumatic arthritis.
- B) Revision of failed femoral head replacement, cup arthroplasty or other hip procedures.
- C) Proximal femoral fractures.
- D) Avascular necrosis of the femoral head.
- E) Non-union of proximal femoral neck fractures.
- F) Other indications such as congenital dysplasia, arthrodesis conversion, coxa magna, coxa plana, coxa vara, coxa valga, developmental conditions, metabolic and tumorous conditions, osteomalacia, osteoporosis, pseudarthrosis conversion, and structural abnormalities
Acetabular components are indicated for cemented and cementless use.
Consensus femoral stems are indicated for cemented and cementless use.
UniSyn femoral stems are indicated for cementless use only.
HA coated implants are indicated for cementless use only.
Product codes (comma separated list FDA assigned to the subject device)
LPH, LZO
Device Description
The Consensus® Hip System (CHS) currently offers a semi-constrained metal-backed acetabular component comprising a porous coated shell manufactured from Titanium alloy (ASTM F620 or F136) (K922561, K020153, K060635) and a mating insert manufactured from ultra-high molecular weight polyethylene (UHMWPE) (K922561) (ASTM F648) or highly crosslinked UHMWPE (ASTM F648) (K021466, K070061). The shell is designed for uncemented press-fit or cemented use to the prepared acetabulum, and is designed to mate with the insert via secure insert/shell locking mechanism. The previously cleared inserts are designed to articulate with the CHS femoral heads.
The CS2™ Plus acetabular insert adds a lateralized configuration to the current line of CHS crosslinked UHMWPE acetabular inserts (i.e. CS2™ inserts) (K021466, K070061). The design intent is to allow the surgeon more intraoperative flexibility to medialize the acetabular cup or lateralize the head center, while maintaining substantial insert wall thickness.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Hip joint
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The risk analysis method used to assess the impact of the modifications was a Failure Modes and Effects Analysis (FMEA). The risk analysis was performed according to the requirements of ISO 14971:2007 "Medical Devices – Application of risk management to medical devices". Records of the risk analysis process are retained in the design history file.
Based upon the fact that the new CS2 Plus Acetabular Inserts represent a line extension of the current CS2 inserts the following preclinical testing/evaluation was preformed:
-
- Torsion testing of insert/shell locking mechanism (CS2 Plus & CS2)
-
- Lever out testing (CS2 Plus & CS2)
-
- Range of motion study (CS2 Plus & CS2)
-
- CAD verification study of locking mechanism (CS2 Plus & CS2)
-
- Push out testing (CS2)
The results of the above testing verify that the new device is substantially equivalent to the predicate device.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
K922561, K990135, K994415, K001534, K010171, K021466, K061253, K070061
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 888.3358 Hip joint metal/polymer/metal semi-constrained porous-coated uncemented prosthesis.
(a)
Identification. A hip joint metal/polymer/metal semi-constrained porous-coated uncemented prosthesis is a device intended to be implanted to replace a hip joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across the joint. This generic type of device has a femoral component made of a cobalt-chromium-molybdenum (Co-Cr-Mo) alloy or a titanium-aluminum-vanadium (Ti-6Al-4V) alloy and an acetabular component composed of an ultra-high molecular weight polyethylene articulating bearing surface fixed in a metal shell made of Co-Cr-Mo or Ti-6Al-4V. The femoral stem and acetabular shell have a porous coating made of, in the case of Co-Cr-Mo substrates, beads of the same alloy, and in the case of Ti-6Al-4V substrates, fibers of commercially pure titanium or Ti-6Al-4V alloy. The porous coating has a volume porosity between 30 and 70 percent, an average pore size between 100 and 1,000 microns, interconnecting porosity, and a porous coating thickness between 500 and 1,500 microns. The generic type of device has a design to achieve biological fixation to bone without the use of bone cement.(b)
Classification. Class II.
0
KI009333
9. 510(K) SUMMARY
DCT & 2010
| Sponsor Name: | Consensus Orthopedics, Inc.
1115 Windfield Way, Suite 100
El Dorado Hills, CA 95762 |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------|
| 510(k) Contact: | Matthew M. Hull, RAC
Phone: (916) 355-7156
Fax: (916) 355-7190
mhull@consensusortho.com |
| Date Prepared: | 1 October 2010 |
| Trade Name: | CS2™ Plus Acetabular Insert |
| Common Name: | Cross Linked Polyethylene, Lateralized, Acetabular Insert |
| Classification Name: | Hip joint metal/polymer/metal semi-constrained porous-coated
uncemented prosthesis (21 CFR 888.3358, Product Code LPH) |
| | Hip joint metal/ceramic/polymer semi-constrained cemented or
nonporous uncemented prosthesis (21 CFR 888.3353, Product Code
LZO) |
| Regulatory Class: | Class II |
Device Classification Panel: Orthopedic Devices
Predicate Device Identification:
The intended use, materials, and design features of the subject CS27M Plus acetabular insert are substantially equivalent to those of predicate devices manufactured by Consensus Orthopedics and competitors (Table 9.1). The safety and effectiveness of the CS2™ Plus insert are adequately supported by the substantial equivalence information and materials data provided within this Special 510(k) submission.
| 510(k)
Number | Trade Name | 510(k) holder | 510(k) Clearance
Date |
|------------------|-----------------------------------------------------------------|-----------------------------|--------------------------|
| K922561 | Consensus™ Total Hip System | Consensus Orthopedics, Inc. | 07/21/1993 |
| K990135 | Trilogy Acetabular System Longevity
Crosslinked Polyethylene | Zimmer, Inc. | 07/12/1999 |
| K994415 | Marathon Cross-linked Polyethylene
Acetabular Cup Liners | DePuy Orthopaedics, Inc. | 02/03/2000 |
| K001534 | Pinnacle Acetabular Cup System | DePuy Orthopaedics, Inc. | 06/12/2000 |
Table 9.1: Predicate device summary table.
Page 1 of 4
1
| K010171 | Duraloc Acetabular Cup System, 36mm
Marathon +4 Polyethylene Liner | DePuy Orthopaedics, Inc. | 04/06/2001 |
|---------|-----------------------------------------------------------------------|-----------------------------|------------|
| K021466 | Consensus Acetabular Insert, Cross-
Linked Polyethylene (CS2TM) | Consensus Orthopedics, Inc. | 07/24/2002 |
| K061253 | Reflection 3 Acetabular System | Smith & Nephew | 05/31/2006 |
| K070061 | 36mm CoCr Femoral Head and 36mm
Acetabular Insert (CS2™) | Consensus Orthopedics, Inc. | 01/31/2007 |
Indications for use with the CONSENS® Hip System or UNISYN™ Hip System:
- A) Significantly impaired joints resulting from rheumatoid, osteo, and post-traumatic arthritis.
- B) Revision of failed femoral head replacement, cup arthroplasty or other hip procedures.
- C) Proximal femoral fractures.
- D) Avascular necrosis of the femoral head.
- E) Non-union of proximal femoral neck fractures.
- F) Other indications such as congenital dysplasia, arthrodesis conversion, coxa magna, coxa plana, coxa vara, coxa valga, developmental conditions, metabolic and tumorous conditions, osteomalacia, osteoporosis, pseudarthrosis conversion, and structural abnormalities
Acetabular components are indicated for cemented and cementless use.
Consensus femoral stems are indicated for cemented and cementless use.
UniSyn femoral stems are indicated for cementless use only.
HA coated implants are indicated for cementless use only.
Device Description:
The Consensus® Hip System (CHS) currently offers a semi-constrained metal-backed acetabular component comprising a porous coated shell manufactured from Titanium alloy (ASTM F620 or F136) (K922561, K020153, K060635) and a mating insert manufactured from ultra-high molecular weight polyethylene (UHMWPE) (K922561) (ASTM F648) or highly crosslinked UHMWPE (ASTM F648) (K021466, K070061). The shell is designed for uncemented press-fit or cemented use to the prepared acetabulum, and is designed to mate with the insert via secure insert/shell locking mechanism. The previously cleared inserts are designed to articulate with the CHS femoral heads.
The CS2™ Plus acetabular insert adds a lateralized configuration to the current line of CHS crosslinked UHMWPE acetabular inserts (i.e. CS2™ inserts) (K021466, K070061). The design intent is to allow the surgeon more intraoperative flexibility to medialize the acetabular cup or lateralize the head center, while maintaining substantial insert wall thickness.
Comparison of Technological Characteristics:
The following features are common for the CS2™ Plus insert and the previously cleared CS2™ insert:
Page 2 of 4
2
K100933
- Manufactured from DePuy Marathon® crosslinked UHMWPE (ASTM F648, (K994415). .
- Compatible with previously cleared CHS acetabular shells (K922561, K020153, . K060635), CHS femoral stems (K922561, K933499, K935453, K935193), CHS femoral heads (K953792, K960156, K030151, K070061), and UniSyn™ Hip System components (K003649, K062383) of the appropriate size.
- Identical articular surfaces designed to mate with 28mm, 32mm, and 36mm diameter . femoral heads.
- 28mm ID inserts accommodate the same number of shell sizes. .
- . Neutral and hooded configurations.
- o Hooded configurations feature an identical Titanium X-ray marker (ASTM F136).
- 0 28mm and 32mm inserts offer neutral or 20° hooded configurations.
- Minimum wall thickness at dome apex greater than 5mm. ●
- Identical insert/shell locking mechanism. .
- Identical minimum intended range of motion. .
The following features are unique to the CS2™ Plus insert in comparison to the previously cleared CS2TM insert:
- The CS2™ Plus insert is designed to position the femoral head center 5mm more laterally . than that of the CS2TM insert.
- 32mm CS2™ Plus insert will accommodate two additional shell sizes (48 and 50mm . OD), which are currently only compatible with 28mm CS2™ inserts.
- 36mm CS2™ Plus insert will accommodate two additional shell sizes (52 and 54mm . OD), which are currently only compatible with 28mm and 32mm CS2TM inserts.
- Will not accommodate 22mm heads. .
- 36mm CS2™ Plus inserts offer neutral or 10° hooded configurations, whereas the 36mm . CS2™ inserts offer neutral, 10°, or 20° hooded configurations.
- The CS2™ Plus insert will have an increased wall thickness at the apex of the dome and . beneath the external snap feature due to the 5mm lateral offset.
- When mated with the acetabular shell, the CS2™ Plus insert will extend further outside . the shell by 5mm due to the 5mm lateral offset of the head center.
Summary of Nonclinical Testing and Evaluation:
The risk analysis method used to assess the impact of the modifications was a Failure Modes and Effects Analysis (FMEA). The risk analysis was performed according to the requirements of ISO 14971:2007 "Medical Devices – Application of risk management to medical devices". Records of the risk analysis process are retained in the design history file.
Based upon the fact that the new CS2 Plus Acetabular Inserts represent a line extension of the current CS2 inserts the following preclinical testing/evaluation was preformed:
-
- Torsion testing of insert/shell locking mechanism (CS2 Plus & CS2)
-
- Lever out testing (CS2 Plus & CS2)
-
- Range of motion study (CS2 Plus & CS2)
Page 3 of 4
3
K 100933
-
- CAD verification study of locking mechanism (CS2 Plus & CS2)
-
- Push out testing (CS2)
The results of the above testing verify that the new device is substantially equivalent to the predicate device.
Page 4 of 4
・。
4
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" around the perimeter. Inside the circle is a stylized image of an eagle or other bird with its wings spread.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room W-O66-0609 Silver Spring, MD 20993-0002
Consensus Orthopedics, Inc. % Mr. Matthew M. Hull, RAC Director QS & RA 1115 Windfield Way Suite 100 El Dorado Hills, California 95762
OCT 6 2010
Re: K100933
Trade/Device Name: CONSENSUS® Hip System: CS2™ Plus Acetabular Insert Regulation Number: 21 CFR 888.3358
Regulation Name: Hip joint metal/polymer/metal semi-constrained porous-coated uncemented prosthesis
Regulatory Class: Class II Product Code: LPH, LZO Dated: September 10, 2010 Received: September 15, 2010
Dear Mr. Hull:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Iisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical
. I
.. ' ...
5
Page 2 - Mr. Matthew M. Hull, RAC
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH0ffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
cerely yours,
for Nollm Din
Mark N. Melkerson Director Division of Surgical, Orthopedic, and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
Indications for Use
510(k) Number: K100933
Device Name: CONSENSUS® Hip System: CS2TM Plus Acetabular Insert
Indications for use with the CONSENSUS® Hip System or UNISYN™ Hip System
- A ) Significantly impaired joints resulting from rheumatoid, osteo, and post-traumatic arthritis.
- B) Revision of failed femoral head replacement, cup arthroplasty or other hip procedures.
- C) Proximal femoral fractures.
- D) Avascular necrosis of the femoral head.
- E) Non-union of proximal femoral neck fractures.
- F) Other indications such as congenital dysplasia, arthrodesis conversion, coxa magna, coxa plana, coxa vara, coxa valga, developmental conditions, metabolic and tumorous conditions, osteomalacia, osteoporosis, pseudarthrosis conversion, and structural abnormalities
Acetabular components are indicated for cemented and cementless use. Consensus femoral stems are indicated for cemented and cementless use. UniSyn femoral stems are indicated for cementless use only. HA coated implants are indicated for cementless use only.
Prescription Use_ X (21 CFR. Part 801 Subpart D) AND/OR
Over the Counter Use (21 CFR Part 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE, CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Soutu for nxm
(Division Sign-Off)
Division of Surgical, Grinopedic, and Restorative Devices
510(k) Number K100933